Pharmacokinetics of BAY 59-7939 - An oral, direct Factor Xa inhibitor - In rats and dogs

Xenobiotica

Volumn 35, Issue 9, 2005, Pages 891-910

  Weinz, C ^a   Buetehorn, U ^a   Daehler, H P ^a   Kohlsdorfer, C ^a   Pleiss, U ^a   Sandmann, S ^a   Schlemmer, K H ^a   Schwarz, T ^a   Steinke, W ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Absorption; Distribution; Excretion; Factor Xa inhibitor; Pharmacokinetics; Preclinical; Protein binding; Whole body autoradiography

Indexed keywords

5 CHLORO N [[2 OXO 3 [4 (3 OXO 4 MORPHOLINYL)PHENYL] 1,3 OXAZOLIDIN 5 YL]METHYL] 2 THIOPHENECARBOXAMIDE; BLOOD CLOTTING FACTOR 10A INHIBITOR; RIVAROXABAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; EXPERIMENTAL MODEL; FEMALE; MALE; NONHUMAN; RADIOACTIVITY; RAT; WHOLE BODY AUTORADIOGRAPHY;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; DOGS; ENZYME INHIBITORS; FACTOR XA; FEMALE; MALE; MORPHOLINES; RATS; RATS, WISTAR; THIOPHENES;

ANIMALIA; CANIS FAMILIARIS;

EID: 28744443405     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250500250493     Document Type: Article

References (18)

1. Allen L, Kimura K, McKichan J, Ritschel WA. 1982. Manual of symbols, equations & definitions in pharmacokinetics. Journal of Clinical Pharmacology 22:1S-23S.
2. Boxenbaum H. 1980. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin. Journal of Pharmacokinetics and Biopharmaceutics 8:165-176.
3. Charter MK. 1989. The estimation of moments: A technical note. Journal of Pharmacokinetics and Biopharmaceutics 17:203-208.
4. Curtis CG, Cross SAM, McCulloch RJ, Powell GM. 1981. Whole-body autoradiography. London: Academic Press.
5. Duhm B, Maul W, Medenwald H, Patzschke K, Wegner LA. 1972. [Animal experiments on pharmacokinetic and biotransformation of radioactively labelled 4-(2′-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethly ester]. Arzneimittelforschung 22:42. [in German].
6. FDA. 2000. Analytical procedures and methods validation: Chemistry, manufacturing, and controls. Federal Register (Notices) 65:52776-52777.
7. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. 2003. Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects. Blood 102: abst 3004.
8. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. 2005. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939 - an oral, direct factor Xa inhibitor. Clinical Pharmacology and Therapeutics, in press.
9. Lin JH. 1998. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metabolism and Disposition 26:1202-1212.
10. Mann KG, Brummel K, Butenas S. 2003. What is all that thrombin for? Journal of Thrombosis and Haemostasis 1:1504-1514.
11. Perzborn EP, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer K-H, Straub A. 2005. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. Journal of Thrombosis and Haemostasis 3:514-521.
12. Petitpas J, Bhattacharya A, Twine S, East M, Curry S. 2001. Crystal structure analysis of Warfarin binding to human serum albumin. Journal of Biological Chemistry 276:22804-22809.
13. Rowland M, Tozer TN. 1995. Clinical pharmacokinetics - concepts and applications. 3rd ed. Baltimore, PA: Williams & Wilkins.
14. Scholtan W, Schmid J. 1963. Die Bindung der Penecilline an die Eiweisskörper des Serums und des Gewebes. Arzneimittelforschung 12:741-750 [in German].
15. Vorum H, Honore B. 1996. Influence of fatty acids on the binding of Warfarin and Phenprocoumon to human serum albumin with relation to anticoagulant therapy. Journal of Pharmacy and Pharmacology 48:870-875.
16. Weinz C, Radtke M, Schmeer K, Kern A, Pleiss U. 2004a. In vitro metabolism of BAY 59-7939 - an oral direct Factor Xa inhibitor. Drug Metabolism Reviews 36(Suppl. 1): 98 (abst 195).
17. 14C]BAY 59-7939 - an oral, direct Factor Xa inhibitor - in rat, dog, and human. Drug Metabolism Reviews 36(Suppl. 1): 98 (abst 196).
18. Yamaoka K, Nakagawa T, Uno T. 1978. Statistical moments in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 6:547-558.